Analyst Recommendations On State Bank Of India

Analyst Recommendations On State Bank Of India

Analyst Recommendations On State Bank Of India

  • Maintains ‘buy’ rating; raises price target to Rs 560 apiece from Rs 385.
  • Strong NII provision; large buffer built for employee provisioning.
  • Asset quality is delivering better outcomes versus even private banks.
  • Revises earnings estimates higher by 15-26% and expects RoEs of 14% by FY23.
  • Expects material re-rating beyond 1x book.
  • Still remains a deep value opportunity and current re-rating should continue.

READ MORE…

Stocks to Watch: State Bank of India, IndiGo, Infosys, Nestle India

Infosys: The Schall Law Firm, a shareholder rights litigation firm based in Los Angeles has announced the filing of a class action lawsuit against Infosys Limited. It alleged that Infosys made false and misleading statements to the market and used improper recognition of revenue to boost short-term profits.

READ MORE…

Bad news for SBI customers

Bad news for SBI customers! SBI halves daily ATM withdrawal on THESE debit cards to Rs 20,000 from 31 October

As per a senior SBI official, the average cash withdrawal from ATMs per card is less than Rs 20,000 and the move will help in checking frauds and promote digital transaction. About a month ago, the State Bank of India (SBI) had alerted its customers holding Classic and Maestro debit cards regarding reduction of cash withdrawal limit to Rs 20,000 a day from ATM starting October 31.

READ MORE…

Banks Collect Rs 5,000 Crore From Minimum Balance Penalty

Gold Silver Reports (GSR) – As many as 21 public sector banks and three major private sector lenders collected a whopping Rs 5,000 crore from customers for non-maintenance of minimum balance in their accounts in 2017-18, according to banking data.              

READ MORE…

Stocks Check : Cipla, State Bank Of India And More

Stocks Check: Cipla, State Bank Of India And More 📌 State Bank of India won’t be able to merge more banks with self.        📌 UPL-led consortium is in exclusive talks to acquire Bill Ackman-backed Platform Specialty Products Corp.  📌 Cipla gets final approval for generic drug Sustiva.  📌 The wealth management …

READ MORE…